Infections with the human immunodeficiency virus, which inevitably lead to the development of AIDS, are still among the most serious global health problems causing more than 2.5 million deaths per year. In the pathophysiological processes of this pandemic, HIV protease has proven to be an invaluable drug target because of its essential role in the virus replication process. By use of pyrrolidine as core structure, symmetric 3,4 bis N alkylsulfonamides were designed and synthesized enantioselectively from d amp; 8722; tartaric acid as a new class of HIV protease inhibitors. Structure guided design using the cocrystal structure of an initial lead as starting point resulted in a second series of inhibitors with improved affinity. The bindi...
Ten years ago, the first protease inhibitor targeting the human immunodeficiency virus (HIV) was app...
In an effort to identify a new class of druglike HIV-1 protease inhibitors, four different stereopur...
Substituted bis-THF containing protease inhibitors were designed to optimize ligand-enzyme interacti...
Infections with the human immunodeficiency virus, which inevitably lead to the development of AIDS, ...
Infections with the human immunodeficiency virus, which inevitably lead to the development of AIDS, ...
Human Immunodeficiency Virus (HIV) is the causative agent of Acquired Immune Deficiency Syndrome (AI...
Based upon molecular insights from the X-ray structures of inhibitor-bound HIV-1 protease complexes,...
Since 1981, HIV/AIDS has affected over 70 million individuals worldwide. Due to the incorporation of...
The proteolytic enzyme of the human immunodeficiency virus (HIV-PR) plays an important role in the H...
A series of new HIV-1 protease inhibitors (PIs) were designed using a general strategy that combines...
HIV-1 protease binds to its peptide/protein substrates in extended conformations. Therefore protease...
wo series of symmetry-based HIV protease inhibitors containing (S,S) or (R,R) tartaric acid core str...
We have developed a conceptually new generation of non-peptidic HIV-1 protease inhibitors incorporat...
Human immunodeficiency virus HIV protease is a well established drug target in HIV chemotherapy. H...
HIV-1 protease is a critical enzyme in the life cycle of the human immunodeficiency virus (HIV). Tar...
Ten years ago, the first protease inhibitor targeting the human immunodeficiency virus (HIV) was app...
In an effort to identify a new class of druglike HIV-1 protease inhibitors, four different stereopur...
Substituted bis-THF containing protease inhibitors were designed to optimize ligand-enzyme interacti...
Infections with the human immunodeficiency virus, which inevitably lead to the development of AIDS, ...
Infections with the human immunodeficiency virus, which inevitably lead to the development of AIDS, ...
Human Immunodeficiency Virus (HIV) is the causative agent of Acquired Immune Deficiency Syndrome (AI...
Based upon molecular insights from the X-ray structures of inhibitor-bound HIV-1 protease complexes,...
Since 1981, HIV/AIDS has affected over 70 million individuals worldwide. Due to the incorporation of...
The proteolytic enzyme of the human immunodeficiency virus (HIV-PR) plays an important role in the H...
A series of new HIV-1 protease inhibitors (PIs) were designed using a general strategy that combines...
HIV-1 protease binds to its peptide/protein substrates in extended conformations. Therefore protease...
wo series of symmetry-based HIV protease inhibitors containing (S,S) or (R,R) tartaric acid core str...
We have developed a conceptually new generation of non-peptidic HIV-1 protease inhibitors incorporat...
Human immunodeficiency virus HIV protease is a well established drug target in HIV chemotherapy. H...
HIV-1 protease is a critical enzyme in the life cycle of the human immunodeficiency virus (HIV). Tar...
Ten years ago, the first protease inhibitor targeting the human immunodeficiency virus (HIV) was app...
In an effort to identify a new class of druglike HIV-1 protease inhibitors, four different stereopur...
Substituted bis-THF containing protease inhibitors were designed to optimize ligand-enzyme interacti...